Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and β-lactams:: SMART program 2001 data

被引:34
作者
Hsueh, PR [1 ]
Teng, LJ
Wu, TL
Yang, D
Huang, WK
Shyr, JM
Chuang, YC
Wan, JH
Yan, JJ
Lu, JJ
Wu, JJ
Ko, WC
Chang, FY
Yan, YC
Lau, YJ
Liu, YC
Lee, CM
Leu, HS
Liu, CY
Luh, KT
机构
[1] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 10018, Taiwan
[2] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10018, Taiwan
[3] Chang Gung Mem Hosp, Taipei 10591, Taiwan
[4] Mackay Mem Hosp, Taipei, Taiwan
[5] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan
[6] Taichung Vet Gen Hosp, Taichung, Taiwan
[7] Chi Mei Med Ctr, Tainan, Taiwan
[8] China Med Coll Hosp, Taichung, Taiwan
[9] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[10] Tri Serv Gen Hosp, Taipei, Taiwan
[11] Taipei Vet Gen Hosp, Taipei, Taiwan
关键词
D O I
10.1128/AAC.47.7.2145-2151.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
There is a high prevalence of beta-lactam- and macrolide-resistant Streptococcus pneumoniae in Taiwan. To understand the in vitro susceptibilities of recent isolates of S. pneumoniae to fluoroquinolones and telithromycin (which is not available in Taiwan), the MICs of 23 antimicrobial agents for 936 clinical isolates of S. pneumoniae isolated from different parts of Taiwan from 2000 to 2001 were determined by the agar dilution method. Overall, 72% of isolates were not susceptible to penicillin (with 61% being intermediate and 11% being resistant) and 92% were resistant to erythromycin. Telithromycin MICs were greater than or equal to1 mug/ml for 16% of the isolates, and for 99% of these isolates the MICs of all macrolides tested were greater than or equal to256 mug/ml; all of these isolates had the constitutive macrolide-lincosamide-streptogramin B phenotype. Eighty-eight percent of the isolates were resistant to three or more classes of drugs. The ciprofloxacin MICs were greater than or equal to4 mug/ml for six (0.6%) isolates from five patients collected in 2000 and 2001, and the levofloxacin MICs were greater than or equal to8 mug/ml for five of these isolates. Seven isolates for which ciprofloxacin MICs were greater than or equal to4 mug/ml, including one isolate recovered in 1999, belonged to three serotypes (serotype 19F, five isolates; serotype 23A, one isolate; and serotype 23B, one isolate). The isolates from the six patients for which ciprofloxacin MICs were greater than or equal to4 mug/ml had different pulsed-field gel electrophoresis profiles and random amplified polymorphic DNA patterns, indicating that no clonal dissemination occurred over this time period. Despite the increased rate of fluoroquinolone use, the proportion of pneumococcal isolates for which ciprofloxacin MICs were elevated (greater than or equal to4 mug/ml) remained low. However, the occurrence of telithromycin resistance is impressive and raises concerns for the future.
引用
收藏
页码:2145 / 2151
页数:7
相关论文
共 38 条
[21]   Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan [J].
Hsueh, PR ;
Teng, LJ ;
Lee, LN ;
Yang, PC ;
Ho, SW ;
Luh, KT .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (04) :897-901
[22]   Dissemination of high-level penicillin-, extended-spectrum cephalosporin-, and erythromycin-resistant Streptococcus pneumoniae clones in Taiwan [J].
Hsueh, PR ;
Teng, LJ ;
Lee, LN ;
Yang, PC ;
Ho, SW ;
Luh, KT .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (01) :221-224
[23]   First clinical isolate of Streptococcus pneumoniae exhibiting high-level resistance to fluoroquinolones in Taiwan [J].
Hsueh, PR ;
Teng, LJ ;
Wu, TL ;
Ho, SW ;
Luh, KT .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (02) :316-317
[24]   In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species [J].
Jalava, J ;
Kataja, J ;
Seppälä, H ;
Huovinen, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :789-793
[25]   Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States [J].
Jones, ME ;
Staples, AM ;
Critchley, I ;
Thornsberry, C ;
Heinze, P ;
Engler, HD ;
Sahm, DF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) :2645-2652
[26]   In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program [J].
Jones, RN ;
Pfaller, MA .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S16-S23
[27]   Macrolide and fluoroquinolone (Levofloxacin) resistances among Streptococcus pneumoniae strains:: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999) [J].
Jones, RN ;
Pfaller, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :4298-4299
[28]   Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America [J].
Karlowsky, JA ;
Nealy, L ;
Sahm, DF ;
Thornsberry, C ;
Jones, ME .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) :2748-2749
[29]   The emergence of resistance to levofloxacin before clinical use in a university hospital in Singapore [J].
Kumarasinghe, G ;
Chow, C ;
Tambyah, PA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :862-863
[30]   Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan [J].
Luh, KT ;
Hsueh, PR ;
Teng, LJ ;
Pan, HJ ;
Chen, YC ;
Lu, JJ ;
Wu, JJ ;
Ho, SW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3374-3380